USPTO Grants Quick-Med Technologies Patent Covering NIMBUS(R) Antimicrobial Bonding Method
11 Janvier 2012 - 2:00PM
Quick-Med Technologies, Inc. (OTCQB:QMDT), a life sciences company
that is developing innovative technologies for the healthcare and
consumer markets, announced today that it had been awarded a
seventh U.S. patent for its novel, non-leaching NIMBUS®
antimicrobial technology.
The U.S. Patent and Trademark Office has issued Quick-Med
Technologies U.S. Patent No. 8,092,854 entitled "Method of
Attaching an Antimicrobial Cationic Electrolyte to the Surface of a
Substrate." The new patent covers the method of production that
non-leachably bonds NIMBUS antimicrobials to various treated
substrates.
The newly granted patent covers the process of attaching members
of the NIMBUS family of antimicrobials to substrates that are whole
or in part cellulosic or any of a list of other substrates
including such polymerics as polyurethane, polyester, nylon and
acrylics, as well as silk, linen, rubber, alginates and collagen
among many others. These are materials that are commonly used in
textile and medical products, filters, absorbent products and
packaging.
"Our non-leachable bonding of the antimicrobial agent
distinguishes NIMBUS from other antimicrobial materials which
require release of the active agent in order to function," said J.
Ladd Greeno, Quick-Med CEO. "We are very pleased that USPTO has
granted this key NIMBUS patent."
"This newest of the Quick-Med Technologies series of patents is
a keystone of the NIMBUS technology in that it covers the process
of treating materials such that they become permanent barriers to
the transmission of microorganisms," said Dr. Jerry Olderman,
Quick-Med's vice president of Research & Development.
While NIMBUS antimicrobials remain at full strength, the active
agent in most other antimicrobial technologies is depleted
gradually while in use. These other antimicrobials carry the risk
of irritation or interference with healing in products such as
wound dressings and textile applications in which the treated
material is next to or used on the skin.
The bonding of an antimicrobial to a substrate is a paradigm
shift from the current state-of-the-art which fosters release of
the active agent. The value of a non-leaching antimicrobial is
that it does not allow depletion of the active agent which can lead
to damage to human skin or tissue cells such that they can cause
irritation, delay healing and possibly initiate the development of
bacterial resistance.
About NIMBUS
Quick-Med's patented technology, NIMBUS, is a cutting-edge
antimicrobial technology that has been custom designed for wound
care and other medical applications. NIMBUS received De Novo
FDA clearance in 2009 and has been commercialized in traditional
wound care applications. It is the only non-leaching
antimicrobial dressing which, by design, poses no risk of bacteria
developing resistance. NIMBUS technology is protected by twelve
U.S. patents and patents pending and 24 foreign counterparts.
Additional applications under development include advanced wound
dressings, medical adhesives, and catheters.
About Quick-Med Technologies, Inc.
Quick-Med Technologies, Inc. is a life sciences company that is
developing proprietary, broad-based technologies for infection
prevention and control in the consumer and healthcare markets. In
addition to NIMBUS, Quick-Med's Stay Fresh® technology provides
highly durable antimicrobial protection for laundered apparel and
other textile applications and its NimbuDerm™ technology is being
developed as a long-lasting hand sanitizer. For more information,
see: www.quickmedtech.com.
The Quick-Med Technologies, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=8260
© 2012 Quick-Med Technologies, Inc. All rights reserved. NIMBUS®
and Stay Fresh® are registered trademarks and NimbuDerm™ is a
trademark of Quick-Med Technologies, Inc.
Forward-looking statements (statements which are not historical
facts) in this release are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
For this purpose, any statements contained in this release that are
not statements of historical fact may be deemed to be
forward-looking statements. Without limiting the generality of the
foregoing, words such as "may", "will", "to", "expect", "plan",
"believe", "anticipate", "intend", "could", "would", "estimate",
and/or "continue" or the negative or other variations thereof or
comparable terminology are intended to identify forward-looking
statements involve risks and uncertainties, including those risks
that are discussed in the Company's filings with the Securities and
Exchange Commission ("SEC"), which may be accessed at the SEC's
Edgar System at www.sec.gov.
CONTACT: Quick-Med Technologies, Inc
Jerry Olderman, Ph.D., VP, R&D
(888) 835.2211 Ext 104
jolderman@quickmedtech.com
Stonegate Securities, Inc.
Casey Stegman (investor/media contact)
(214) 987-4121
casey@stonegateinc.com
Quick Med Technologies (CE) (USOTC:QMDT)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Quick Med Technologies (CE) (USOTC:QMDT)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024